eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2024
vol. 10
 
Share:
Send email
Share:
abstract:
Original paper

Treatment of HCV infection in patients with steatotic liver disease

Robert Flisiak
1
,
Dorota Zarębska-Michaluk
2
,
Krystyna Dobrowolska
3
,
Justyna Janocha-Litwin
4
,
Dorota Dybowska
5
,
Marek Sitko
6
,
Łukasz Socha
7
,
Beata Lorenc
8
,
Jakub Klapaczyński
9
,
Jakub Brodowski
10

  1. Department of Infectious Diseases and Hepatology, Medical University of Białystok, Poland
  2. Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce, Poland
  3. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  4. Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland
  5. Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
  6. Department of Infectious and Tropical Diseases, Jagiellonian University, Kraków, Poland
  7. Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland
  8. Pomeranian Center of Infectious Diseases, Gdańsk, Poland
  9. Department of Internal Medicine and Hepatology, the National Institute of Medicine of the Ministry of Interior and Administration, Warsaw, Poland
  10. Faculty of Medicine, Medical University of Białystok, Białystok, Poland
Clin Exp HEPATOL 2024; 10, 3: 159-164
DOI: https://doi.org/10.5114/ceh.2024.141699
Online publish date: 2024/07/23
View full text Get citation
 
PlumX metrics:
Aim of the study:
The aim of the study was to characterize the population with hepatitis C virus (HCV) infection and steatotic liver disease (SLD) in comparison to the non-SLD HCV-infected patients and to evaluate the effectiveness of treatment with direct-acting antivirals (DAA).

Material and methods:
The analysis included 62 patients diagnosed with SLD and 14,284 non-SLD patients from the EpiTer-2 database for the period 2015-2022.

Results:
Unlike the non-SLD population, the SLD group was dominated by men (49.5% vs. 53.2%, respectively). The mean age of patients did not differ significantly between groups and was 50.8 ±13.8 and 50.8 ±14.9 years for SLD and non-SLD, respectively. As expected, patients with SLD had significantly different BMI values. Genotype (GT) 1b infection predominated in both populations, but the prevalence of GT3 was significantly higher in the SLD group (19.4% vs. 10.6%). The percentage of patients with advanced liver disease (F3/4) was similar in both groups (38.7% vs. 35.6%). Patients with SLD were more likely to be treatment naïve (82.3% vs. 80.5%), HBV co-infected (24.2% vs. 13.6%), and obese (54.8% vs. 17.1%). Out of 62 patients, 59 (95%) achieved a sustained virologic response (SVR), but after excluding 3 lost to follow-up a response rate of 100% was obtained. The corresponding SVR values in the non-SLD HCV-infected population were 95% and 98%, respectively.

Conclusions:
Despite some differences in the characteristics of patients with SLD infected with HCV, the effectiveness of DAA therapy does not differ significantly from that observed in the general population infected with HCV.

keywords:

treatment, liver, HCV, steatotic liver disease
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.